Scleroderma epidemiology and demographics: Difference between revisions

Jump to navigation Jump to search
m (Bot: Removing from Primary care)
 
(14 intermediate revisions by 3 users not shown)
Line 4: Line 4:
{{CMG}}; {{AE}} {{MKA}}  
{{CMG}}; {{AE}} {{MKA}}  
==Overview==
==Overview==
The majority of cases of scleroderma have been reported from the United States. The [[prevalence]] of scleroderma is approximately 24 cases per 100,000 individuals in the United States. Scleroderma commonly affects individuals between 20 to 50 years of age. Choctaw native Americans have a much higher [[prevalence]] of scleroderma than the general population. Females are more commonly affected than males. Familial clustering of scleroderma has been reported in United States and Australia.


==Epidemiology and Demographics==
==Epidemiology and Demographics==
===Incidence===
===Incidence===
*The incidence of scleroderma is approximately 2 per 100,000 individuals in the United States.<ref name="pmid12841293">{{cite journal |vauthors=Mayes MD |title=Scleroderma epidemiology |journal=Rheum. Dis. Clin. North Am. |volume=29 |issue=2 |pages=239–54 |date=May 2003 |pmid=12841293 |doi= |url=}}</ref>
*The [[incidence]] of scleroderma is approximately 0.23 to 2.28 cases per 100,000 individuals worldwide.<ref name="pmid17692364">{{cite journal |vauthors=Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J |title=Incidence and prevalence of systemic sclerosis: a systematic literature review |journal=Semin. Arthritis Rheum. |volume=37 |issue=4 |pages=223–35 |date=February 2008 |pmid=17692364 |doi=10.1016/j.semarthrit.2007.05.003 |url=}}</ref>
*The [[incidence]] of scleroderma is approximately 2 per 100,000 individuals in the United States.<ref name="pmid12841293">{{cite journal |vauthors=Mayes MD |title=Scleroderma epidemiology |journal=Rheum. Dis. Clin. North Am. |volume=29 |issue=2 |pages=239–54 |date=May 2003 |pmid=12841293 |doi= |url=}}</ref>


===Prevalence===
===Prevalence===
*In 1990, the prevalence of scleroderma was estimated to be 27.6 cases per 100,000 individuals in the united states.<ref name="pmid17692364">{{cite journal |vauthors=Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J |title=Incidence and prevalence of systemic sclerosis: a systematic literature review |journal=Semin. Arthritis Rheum. |volume=37 |issue=4 |pages=223–35 |date=February 2008 |pmid=17692364 |doi=10.1016/j.semarthrit.2007.05.003 |url=}}</ref>
*The [[prevalence]] of scleroderma is approximately 5 to 30 cases per 100,000 individuals worldwide.<ref name="pmid17692364">{{cite journal |vauthors=Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J |title=Incidence and prevalence of systemic sclerosis: a systematic literature review |journal=Semin. Arthritis Rheum. |volume=37 |issue=4 |pages=223–35 |date=February 2008 |pmid=17692364 |doi=10.1016/j.semarthrit.2007.05.003 |url=}}</ref>
*The prevalence of scleroderma is approximately 24 cases per 100,000 individuals in the United States.<ref name="pmid12841293">{{cite journal |vauthors=Mayes MD |title=Scleroderma epidemiology |journal=Rheum. Dis. Clin. North Am. |volume=29 |issue=2 |pages=239–54 |date=May 2003 |pmid=12841293 |doi= |url=}}</ref>
*In 1990, the [[prevalence]] of scleroderma was estimated to be 27.6 cases per 100,000 individuals in the united states.<ref name="pmid17692364">{{cite journal |vauthors=Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J |title=Incidence and prevalence of systemic sclerosis: a systematic literature review |journal=Semin. Arthritis Rheum. |volume=37 |issue=4 |pages=223–35 |date=February 2008 |pmid=17692364 |doi=10.1016/j.semarthrit.2007.05.003 |url=}}</ref>
*The [[prevalence]] of scleroderma is approximately 24 cases per 100,000 individuals in the United States.<ref name="pmid12841293">{{cite journal |vauthors=Mayes MD |title=Scleroderma epidemiology |journal=Rheum. Dis. Clin. North Am. |volume=29 |issue=2 |pages=239–54 |date=May 2003 |pmid=12841293 |doi= |url=}}</ref>


===Case-fatality rate/Mortality rate===
===Standardized mortality ratio===
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate/mortality rate of [number range]%.
*The [[standardized mortality ratio]] of scleroderma is approximately 1.5 to 7.2.<ref name="pmid15639201">{{cite journal |vauthors=Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA, Lucas M, Michet CJ, Kuwana M, Yasuoka H, van den Hoogen F, Te Boome L, van Laar JM, Verbeet NL, Matucci-Cerinic M, Georgountzos A, Moutsopoulos HM |title=Mortality in systemic sclerosis: an international meta-analysis of individual patient data |journal=Am. J. Med. |volume=118 |issue=1 |pages=2–10 |date=January 2005 |pmid=15639201 |doi=10.1016/j.amjmed.2004.04.031 |url=}}</ref>
*The case-fatality rate/mortality rate of [disease name] is approximately [number range].


===Age===
===Age===
*Patients of all age groups may develop [disease name].
*Scleroderma commonly affects individuals between 20 to 50 years of age.<ref name="pmid24646463">{{cite journal |vauthors=Alba MA, Velasco C, Simeón CP, Fonollosa V, Trapiella L, Egurbide MV, Sáez L, Castillo MJ, Callejas JL, Camps MT, Tolosa C, Ríos JJ, Freire M, Vargas JA, Espinosa G |title=Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients |journal=Medicine (Baltimore) |volume=93 |issue=2 |pages=73–81 |date=March 2014 |pmid=24646463 |pmc=4616306 |doi=10.1097/MD.0000000000000018 |url=}}</ref>
*The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
*Scleroderma may also occur in patients younger than 20 years or older than 50 years.
*[Disease name] commonly affects individuals younger than/older than [number of years] years of age.
*[Chronic disease name] is usually first diagnosed among [age group].
*[Acute disease name] commonly affects [age group].


===Race===
===Race===
*Choctaw native americans from southeastern Oklahoma were reported to have much higher prevalence of scleroderma than the general population.<ref name="pmid8702445">{{cite journal |vauthors=Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge TJ, Weathers PE, Reveille JD |title=Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype |journal=Arthritis Rheum. |volume=39 |issue=8 |pages=1362–70 |date=August 1996 |pmid=8702445 |doi= |url=}}</ref>
*Choctaw native Americans from southeastern Oklahoma were reported to have much higher [[prevalence]] of scleroderma than the general population.<ref name="pmid8702445">{{cite journal |vauthors=Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge TJ, Weathers PE, Reveille JD |title=Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype |journal=Arthritis Rheum. |volume=39 |issue=8 |pages=1362–70 |date=August 1996 |pmid=8702445 |doi= |url=}}</ref>
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
*Scleroderma usually affects individuals of the African-American race more than the caucasian race.<ref name="pmid12628048">{{cite journal |vauthors=Reveille JD |title=Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations |journal=Curr Rheumatol Rep |volume=5 |issue=2 |pages=160–7 |date=April 2003 |pmid=12628048 |doi= |url=}}</ref><ref name="pmid12905479">{{cite journal |vauthors=Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D |title=Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population |journal=Arthritis Rheum. |volume=48 |issue=8 |pages=2246–55 |date=August 2003 |pmid=12905479 |doi=10.1002/art.11073 |url=}}</ref>


===Gender===
===Gender===
*Females are more commonly affected by scleroderma than males. The female to male ratio is approximately 4 to 1.<ref name="urlSystemic scleroderma - Genetics Home Reference-US national library of medicine">{{cite web |url=https://ghr.nlm.nih.gov/condition/systemic-scleroderma#sourcesforpage |title=Systemic scleroderma - Genetics Home Reference |format= |work= |accessdate=}}</ref>
*Females are more commonly affected by scleroderma than males. The female to male ratio is approximately ranging from 3:1 to 14:1.<ref name="pmid12905479">{{cite journal |vauthors=Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D |title=Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population |journal=Arthritis Rheum. |volume=48 |issue=8 |pages=2246–55 |date=August 2003 |pmid=12905479 |doi=10.1002/art.11073 |url=}}</ref><ref name="urlSystemic scleroderma - Genetics Home Reference-US national library of medicine">{{cite web |url=https://ghr.nlm.nih.gov/condition/systemic-scleroderma#sourcesforpage |title=Systemic scleroderma - Genetics Home Reference |format= |work= |accessdate=}}</ref>
 
===Region===
===Region===
*The majority of [disease name] cases are reported in [geographical region].
*Scleroderma cases are more frequently reported in the United States than in continental Europe.<ref name="pmid12841293">{{cite journal |vauthors=Mayes MD |title=Scleroderma epidemiology |journal=Rheum. Dis. Clin. North Am. |volume=29 |issue=2 |pages=239–54 |date=May 2003 |pmid=12841293 |doi= |url=}}</ref>
 
*Familial clustering of scleroderma has been reported in United States and Australia.
*[Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
 
===Developed Countries===
 
===Developing Countries===


==References==
==References==
Line 44: Line 39:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category: (name of the system)]]
 
[[Category:Up-To-Date]]
[[Category:Medicine]]
[[Category:Dermatology]]
[[Category:Rheumatology]]

Latest revision as of 00:05, 30 July 2020

Scleroderma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Scleroderma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Scleroderma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Scleroderma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Scleroderma epidemiology and demographics

CDC on Scleroderma epidemiology and demographics

Scleroderma epidemiology and demographics in the news

Blogs on Scleroderma epidemiology and demographics

Directions to Hospitals Treating Scleroderma

Risk calculators and risk factors for Scleroderma epidemiology and demographics

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: M. Khurram Afzal, MD [2]

Overview

The majority of cases of scleroderma have been reported from the United States. The prevalence of scleroderma is approximately 24 cases per 100,000 individuals in the United States. Scleroderma commonly affects individuals between 20 to 50 years of age. Choctaw native Americans have a much higher prevalence of scleroderma than the general population. Females are more commonly affected than males. Familial clustering of scleroderma has been reported in United States and Australia.

Epidemiology and Demographics

Incidence

  • The incidence of scleroderma is approximately 0.23 to 2.28 cases per 100,000 individuals worldwide.[1]
  • The incidence of scleroderma is approximately 2 per 100,000 individuals in the United States.[2]

Prevalence

  • The prevalence of scleroderma is approximately 5 to 30 cases per 100,000 individuals worldwide.[1]
  • In 1990, the prevalence of scleroderma was estimated to be 27.6 cases per 100,000 individuals in the united states.[1]
  • The prevalence of scleroderma is approximately 24 cases per 100,000 individuals in the United States.[2]

Standardized mortality ratio

Age

  • Scleroderma commonly affects individuals between 20 to 50 years of age.[4]
  • Scleroderma may also occur in patients younger than 20 years or older than 50 years.

Race

  • Choctaw native Americans from southeastern Oklahoma were reported to have much higher prevalence of scleroderma than the general population.[5]
  • Scleroderma usually affects individuals of the African-American race more than the caucasian race.[6][7]

Gender

  • Females are more commonly affected by scleroderma than males. The female to male ratio is approximately ranging from 3:1 to 14:1.[7][8]

Region

  • Scleroderma cases are more frequently reported in the United States than in continental Europe.[2]
  • Familial clustering of scleroderma has been reported in United States and Australia.

References

  1. 1.0 1.1 1.2 Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J (February 2008). "Incidence and prevalence of systemic sclerosis: a systematic literature review". Semin. Arthritis Rheum. 37 (4): 223–35. doi:10.1016/j.semarthrit.2007.05.003. PMID 17692364.
  2. 2.0 2.1 2.2 Mayes MD (May 2003). "Scleroderma epidemiology". Rheum. Dis. Clin. North Am. 29 (2): 239–54. PMID 12841293.
  3. Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA, Lucas M, Michet CJ, Kuwana M, Yasuoka H, van den Hoogen F, Te Boome L, van Laar JM, Verbeet NL, Matucci-Cerinic M, Georgountzos A, Moutsopoulos HM (January 2005). "Mortality in systemic sclerosis: an international meta-analysis of individual patient data". Am. J. Med. 118 (1): 2–10. doi:10.1016/j.amjmed.2004.04.031. PMID 15639201.
  4. Alba MA, Velasco C, Simeón CP, Fonollosa V, Trapiella L, Egurbide MV, Sáez L, Castillo MJ, Callejas JL, Camps MT, Tolosa C, Ríos JJ, Freire M, Vargas JA, Espinosa G (March 2014). "Early- versus late-onset systemic sclerosis: differences in clinical presentation and outcome in 1037 patients". Medicine (Baltimore). 93 (2): 73–81. doi:10.1097/MD.0000000000000018. PMC 4616306. PMID 24646463.
  5. Arnett FC, Howard RF, Tan F, Moulds JM, Bias WB, Durban E, Cameron HD, Paxton G, Hodge TJ, Weathers PE, Reveille JD (August 1996). "Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype". Arthritis Rheum. 39 (8): 1362–70. PMID 8702445.
  6. Reveille JD (April 2003). "Ethnicity and race and systemic sclerosis: how it affects susceptibility, severity, antibody genetics, and clinical manifestations". Curr Rheumatol Rep. 5 (2): 160–7. PMID 12628048.
  7. 7.0 7.1 Mayes MD, Lacey JV, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D (August 2003). "Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population". Arthritis Rheum. 48 (8): 2246–55. doi:10.1002/art.11073. PMID 12905479.
  8. "Systemic scleroderma - Genetics Home Reference".

Template:WH Template:WS